Atea Pharmaceuticals, Inc. (AVIR) vs Kyverna Therapeutics, Inc. (KYTX)
A side-by-side comparison of Atea Pharmaceuticals, Inc. and Kyverna Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AVIR
Atea Pharmaceuticals, Inc.
$5.18HealthcareDelayed quote: Oct 6, 2026, 11:34 AM EDT
KYTX
Kyverna Therapeutics, Inc.
$6.40HealthcareDelayed quote: Oct 6, 2026, 11:35 AM EDT
Total return — AVIR vs KYTX
growth of $100 · dividends reinvested · last 3yAVIR +20.4% (+6.4%/yr)KYTX -78.9% (-40.5%/yr)AVIR compounded faster over this window
Log scale — wide-divergence pair
AVIR KYTX
AVIR vs KYTX: by the numbers
- •AVIR is the larger company ($415M vs $389M market cap).
Metrics side by side
Valuation
| Metric | AVIR | KYTX |
|---|---|---|
| P/B ratio | 2.03 | 2.35 |
Profitability
| Metric | AVIR | KYTX |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -80.96% | -92.20% |
| ROIC | -89.93% | -80.67% |
Growth (annualized)
| Metric | AVIR | KYTX |
|---|---|---|
| Total return CAGR (5Y) | -34.44% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.